Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cel ...

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; ...

Company Overview - Sana Biotechnology, Inc. focuses on creating and delivering engineered cells as medicines for patients, aiming to repair and control genes, replace missing or damaged cells, and make therapies broadly available [3] Upcoming Event - Sana will webcast its presentation at the Cowen 45 Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET, featuring a business overview and update by Steve Harr, the President and CEO [1][2] Accessibility of Information - The webcast will be accessible on the Investor Relations page of Sana's website, with a replay available for 30 days following the conference [2]

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana ...

Company Overview - Proactive is a financial news and online broadcast provider delivering fast, accessible, and actionable business and finance news to a global investment audience [1] - The company operates in key finance and investing hubs worldwide, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] Industry Coverage - The company reports on a wide range of industries, including energy companies during global crises, aviation and airlines recovering from the pandemic, and economic, social, and governance issues [1] - Proactive delivers news and unique insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology and Content Production - Proactive is a forward-looking technology adopter, equipping its human content creators with decades of expertise and experience [4] - The company uses automation and software tools, including generative AI, to assist and enhance workflows, but all content is ultimately edited and authored by humans [5] - Proactive follows best practices in content production and search engine optimization [5]

Investment Opportunities - The Haggerston BioHealth marketplace channel offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors [1] - The channel provides access to investment bank-grade financial models, research, and a model portfolio for investors [1] Sana Biotechnology Overview - Sana Biotechnology, Inc (NASDAQ: SANA) completed one of the largest biotech IPOs in history in February 2024 [2] - The company is covered by Edmund Ingham, a biotech consultant with over 5 years of experience in biotech, healthcare, and pharma [2] Research and Analysis Services - Haggerston BioHealth offers detailed reports on over 1,000 companies, including product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [2] - The group provides catalysts, buy/sell ratings, and forecasts for major pharmaceutical companies, catering to both novice and experienced biotech investors [2]

On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression.The study was conducted in partnership with Uppsala University Hospital.Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of c ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 3, 2024.Sana ...